University of Kansas Clinical Research Center

Summary

University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Lung Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 593 conditions. There are 47 research doctors associated with this hospital, such as Jun Zhang, Chao H. Huang, Anwaar Saeed, and Jeffrey Statland.

Top PIs

Clinical Trials running at University of Kansas Clinical Research Center

Lung Cancer

Colorectal Cancer

Bladder Cancer

Acute Myeloid Leukemia

Non-Small Cell Lung Cancer

Cancer

Bladder Carcinoma

Kidney Cancer

Colon Cancer

Acute Myelogenous Leukemia

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3

Iadademstat + Atezolizumab/Durvalumab

for Small Cell Lung Cancer

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.

Recruiting

1 award

Phase 1 & 2

5 criteria

Cemiplimab

for Non-Small Cell Lung Cancer

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2 & 3

19 criteria